Bio-Path Holdings

Bio-Path is a publicly traded biotechnology company focused on developing therapeutic products utilizing its proprietary liposomal delivery technology designed to distribute nucleic acid drugs throughout the human body with a simple intravenous infusion. The Company’s initial focus is on cancer. Bio-Path’s lead product candidate, BP1001 (Liposomal Grb-2), is completing the safety segment of the Phase II for AML in combination with the frontline therapy for induction therapy ineligible patients. A second Phase II safety segment for CML will start in the first half of 2016. Bio-Path’s second drug candidate, also a liposomal antisense drug, is ready for the clinic where it will be evaluated in lymphoma and solid tumors. Bio-Path's antisense DNA - liposomal delivery technology is called DNAbilize™ and is available for licensing for drug development. DNAbilize™ offers distinct advantages over the current antisense and RNAi therapeutics in development. DNAbilize™ chemistry has shown no toxicity in patients to date. This allows for higher dosing to a therapeutic level compared to the more toxic approaches including phosphorothioate DNA. DNAbilize™ also has the advantage of systemic distribution and allows for targeting genes involved in diseases beyond the liver. Systemic level diseases and disorders can be targeted using DNAbilize™. We are interested in collaborations to develop therapeutics using DNAbilize.
Company Growth (employees)
Bellaire, US
Size (employees)
11 (est)
Bio-Path Holdings was founded in 2011 and is headquartered in Bellaire, US

Bio-Path Holdings Office Locations

Bio-Path Holdings has an office in Bellaire
Bellaire, US (HQ)
210 4710 Bellaire Blvd

Bio-Path Holdings Data and Metrics

Bio-Path Holdings Financial Metrics

Bio-Path Holdings's revenue was reported to be $13 k in 2016

Revenue (Y, 2016)

13 k

Net income (Y, 2016)

(6.8 m)

EBIT (Y, 2016)

(8.5 m)

Market capitalization (28-Jun-2017)

38.9 m

Closing share price (28-Jun-2017)


Cash (31-Dec-2016)

9.4 m
Bio-Path Holdings's current market capitalization is $38.9 m.
USDFY, 2013FY, 2014FY, 2015Y, 2016


13 k

Operating expense total

15.7 m4.5 m5.5 m8.5 m


(15.7 m)(4.5 m)(5.5 m)(8.5 m)

EBIT margin, %


Interest income

4 k22.6 k17.7 k12 k

Pre tax profit

(3.3 m)(4.5 m)(5.5 m)

Net Income

(15.4 m)(4.5 m)(5.5 m)(6.8 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016


3.6 m13.9 m8.9 m9.4 m

Current Assets

3.7 m14.1 m9.6 m10.7 m


113.1 k72 k614 k

Total Assets

5.1 m15.5 m10.8 m12.2 m

Accounts Payable

76.1 k41 k54.6 k69 k

Current Liabilities

294.9 k562 k937.4 k1.1 m

Additional Paid-in Capital

20.1 m34.7 m35.1 m40.3 m

Retained Earnings

(19.9 m)(25.4 m)(32.1 m)

Total Equity

4.8 m14.9 m9.8 m8.2 m

Financial Leverage

1.1 x1 x1.1 x1.5 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(3.3 m)(4.5 m)(5.5 m)(6.8 m)

Depreciation and Amortization

10.3 k41.1 k43 k

Accounts Payable

(34.3 k)267.1 k375.4 k(146 k)

Cash From Operating Activities

(2.3 m)(3.8 m)(5 m)(8.1 m)

Cash From Investing Activities

(123.4 k)(338 k)

Cash From Financing Activities

5.3 m14.2 m9 m
Y, 2016

Financial Leverage

1.5 x

Bio-Path Holdings Market Value History

Bio-Path Holdings News and Updates

Bio-Path Holdings Company Life and Culture

You may also be interested in